The Global Personalized Nutrition Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Personalized Nutrition market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/personalized-nutrition-market-12515

Market size & growth

• Global market estimates for personalized nutrition range ~$13.5B (2024) to $17.9B (2025), with CAGRs ~14–17% and projections to $46.9B by 2032 or $60.9B by 2034. North America held ~35.8% share (2023). 

Notable company references (with “values”)

• Viome — >500,000 AI-driven at-home testing kits sold; uses metatranscriptomics; tests priced ~$229–$299, supplements/oral care subs $79–$199/mo; partnered with Microsoft (2025) to optimize AI for molecular health; acquired Habit from Campbell (2019). 

• ZOE — £66m revenue in year to Aug 2024; $15m funding (Jul 2024) to expand in the US; subscription model based on microbiome, CGM & fat tests.

• Nestlé Health Science (NHSc) — acquired Persona (personalized vitamins) Aug 2019; move signals large CPG entry into personalized nutrition.

• DayTwo — microbiome + AI personalized nutrition targeting glycemic control/diabetes; positioned for clinical outcomes use cases.

Recent developments

• Tech-health partnerships: Viome × Microsoft on AI for molecular health (2025).

• Scale-up & US push: ZOE raises $15m and expands in the US (2024); revenue traction noted in 2024.

• CPG consolidation: NHSc acquisition of Persona (2019) expands personalized vitamins.

Drivers

• Rising metabolic disease/obesity burden and shift to preventive health; North America leadership supports premium D2C adoption.

• Advances in omics + AI (metatranscriptomics, microbiome sequencing) enabling actionable insights.

• Proliferation of at-home testing, wearables (CGMs) and subscription supplements for ongoing engagement.

Restraints

• Scientific validation & reproducibility questioned for some consumer apps; risk of over-promising.

• Regulatory gray zones (many offerings classed as wellness, not FDA-regulated).

• Data privacy, cost of multi-omics testing, and health-economics evidence gaps for payers. 

Regional segmentation analysis

• North America: largest share (~35.8% in 2023) with strong D2C and premium adoption. 

• Europe: robust research ecosystem (e.g., UK-based ZOE) and consumer interest; mixed regulatory scrutiny. 

• Asia Pacific: fast growth potential from rising middle class & digital health adoption (varies by country). (Inference from overall market projections + APAC growth notes in syndicated reports).

Emerging trends

• Microbiome-first nutrition and metabolic phenotyping (CGMs, lipid responses).

• AI co-pilots for meal scoring and supplement personalization (e.g., Viome–Microsoft).

• Bundles: test → app → personalized supplements (recurring revenue).

• Clinicalization: RCTs/telemedicine protocols for personalized diet in T2D.

Top use cases

• Metabolic health/diabetes & weight management (glycemic control).

• Gut health & digestive issues (microbiome-guided guidance).

• General wellness & performance nutrition via personalized vitamins and habit coaching.

Major challenges

• Building clinical-grade evidence (hard outcomes) beyond surrogate markers; skepticism from parts of academia/media. 

• Regulatory clarity (claims, LDT/IVD pathways) and payer reimbursement. 

• Data interoperability and safeguarding sensitive multi-omic data. 

Attractive opportunities

• Employer & payer programs for diabetes prevention/management using precision nutrition.

• Partnerships with Big Tech for AI & data infra (e.g., Viome × Microsoft).

• APAC expansion and personalized supplement subscriptions with lower CAC via content/communities.

Key factors of market expansion

1. Validated outcomes from well-designed trials (e.g., T2D telemedicine diet protocols).

2. Affordable, convenient testing and clear UX (kits + apps with actionable nudges). 

3. AI/omics scale-up (metatranscriptomics, microbiome analytics) proving incremental value.

4. Ecosystem partnerships (tech, CPG, providers) and M&A (e.g., NHSc–Persona).

5. Regulatory & reimbursement pathways enabling clinical deployment.

Notes on sources

• I prioritized recent items (2024–2025) for company “values” and market context, and used recognized market reports for sizing. Where I inferred regional growth or opportunity, I’ve flagged it and tied it to the cited market outlooks. If you want, I can turn this into a one-page slide or a table with columns for each section and company references.